GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents, the ...
GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.
Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Teva Pharmaceutical Industries Ltd. ADR 1.52% $19.75B ...
Quant Mid Cap Fund - Direct (G) 225.06 8,29,800 2.52 Quant Large and Mid Cap Fund - Direct (IDCW) 61.30 2,26,000 1.65 Quant Large and Mid Cap Fund - Direct (B) 61.30 2,26,000 1.65 Quant Large and Mid ...
GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
As of November 08, 2024, GSK plc had a $73.1 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc’s price-earnings ratio is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback